Alpha Polyglutamated Raltitrexed Liposomes for Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Raltitrexed therapy for cancer is limited by dose-limiting toxicities and treatment resistance due to lack of tumor selectivity and efflux pump activity, leading to non-specific cytotoxicity and reduced efficacy.
Innovation Solution
Development of alpha polyglutamated raltitrexed compositions, delivered via liposomes, which bypass intracellular conversion mechanisms to directly target cancer cells with higher potency forms, minimizing normal tissue exposure and resistance mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If raltitrexed is administered as monoglutamate form, then it can be transported across cell membrane via RFC, but it requires intracellular polyglutamation to achieve potent TS inhibition and cell retention
Solution Approach 1:
The patent applies preliminary action by pre-converting raltitrexed to alpha-polyglutamated form before cell entry. The compound is synthesized with multiple glutamyl groups already attached (tetraglutamated, pentaglutamated, or hexaglutamated forms), eliminating the need for intracellular conversion and ensuring immediate potent TS inhibition upon cellular uptake.
2Reliability
If conventional raltitrexed therapy is used, then it can inhibit TS enzyme, but dose-limiting toxicities occur due to non-specific cytotoxicity and lack of tumor selectivity
Solution Approach 1:
The patent applies local quality by creating tumor-selective toxicity through multiple mechanisms: (1) Alpha-polyglutamated forms have enhanced affinity for TS enzyme specifically in tumor cells, (2) Folate receptor-mediated targeting delivers the drug preferentially to folate-receptor-positive tumor cells, and (3) The modified structure reduces non-specific binding and off-target effects in normal tissues while maintaining potent anti-TS activity.
3Reliability
If raltitrexed is given at high doses to overcome resistance, then TS inhibition improves, but toxicity to normal tissues increases
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of raltitrexed to create alpha-polyglutamated forms with different pharmacological properties. These modified forms have enhanced TS inhibition potency and improved tumor selectivity, allowing effective treatment at lower doses that reduce normal tissue toxicity while maintaining or improving therapeutic efficacy.
4Reliability
If intracellular polyglutamation occurs, then TS inhibitory potency increases, but the process is dependent on FPGS enzyme activity which may be reduced in resistant cells
Solution Approach 1:
The patent applies the extraction principle by removing the dependency on intracellular FPGS enzyme activity. Instead of relying on cells to convert monoglutamate raltitrexed to polyglutamated forms, the invention directly provides the active alpha-polyglutamated forms (tetraglutamated, pentaglutamated, or hexaglutamated) that can immediately inhibit TS without requiring cellular enzymatic conversion, thereby overcoming FPGS-based resistance mechanisms.
Data Source
AI summary
The disclosure relates generally to alpha polyglutamated raltitrexed, formulations containing liposomes filled with alpha polyglutamated raltitrexed, methods of making the alpha polyglutamated raltitrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated raltitrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).